Watch EW. Know when insiders buy.
One email the day a filing lands. Free.
Work order
35
FLAG · insiders 25, shorts 45
Insiders, 90 days
−$3.3M
net selling · 0 buys, 5 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
2 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $51.8BP/E 51.7DIV YIELD —FCF YIELD 2.77%REV TTM $6.5B +14.6%NET INCOME $1B −75.8%NET CASH $2.3B52W 72.65 – 95.18NEXT EARNINGS Oct 29 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.7B | +13.6% | 77.5% | $513.2M | $241.9M | −27.4% | 0.42 | $651.9M | $66.9M | $585M | Aug 4 |
| Q1 2026 · Mar 31 | $1.6B | +16.7% | 78.0% | $477.6M | $380.7M | +6.3% | 0.66 | $43.8M | $64.9M | −$21.1M | May 6 |
| Q4 2025 · Dec 31derived | $1.6B | +13.3% | 78.1% | $151.1M | $91.2M | −76.3% | 0.16 | $450.9M | $97.4M | $353.5M | Feb 25 |
| Q3 2025 · Sep 30 | $1.6B | +14.7% | 77.8% | $307.1M | $291.1M | −90.5% | 0.50 | $573.7M | $57.5M | $516.2M | Nov 5 |
| Q2 2025 · Jun 30 | $1.5B | +11.9% | 77.5% | $411.2M | $333.2M | −9.0% | 0.56 | $290.2M | $49.3M | $240.9M | Aug 4 |
| Q1 2025 · Mar 31 | $1.4B | +6.2% | 78.7% | $394.8M | $358M | +1.7% | 0.61 | $280.4M | $56M | $224.4M | May 6 |
| Q4 2024 · Dec 31 | $1.4B | +9.4% | 78.9% | $312.6M | $385.6M | +4.2% | 0.65 | −$127.5M | $49.8M | −$177.3M | Feb 25 |
| Q3 2024 · Sep 30 | $1.4B | +8.9% | 80.6% | $350.6M | $3.1B | +697.8% | 5.13 | $351.8M | $51.9M | $299.9M | Nov 5 |
| Q2 2024 · Jun 30 | $1.4B | — | 79.9% | $366.5M | $366.3M | — | 0.61 | $371.5M | $85.4M | $286.1M | Aug 6 |
| Q1 2024 · Mar 31 | $1.3B | — | 78.4% | $349M | $351.9M | — | 0.58 | −$53.5M | $65.3M | −$118.8M | May 6 |
| Q4 2023 · Dec 31 | $1.3B | — | 80.2% | $346.8M | $369.9M | — | 0.61 | $136.6M | $88.3M | $48.3M | Feb 25 |
| Q3 2023 · Sep 30 | $1.2B | — | 79.8% | $365.9M | $384.9M | — | 0.63 | $411.5M | $55.3M | $356.2M | Feb 28 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $6.1B | 78.0% | $1.3B | $1.1B | 17.7% | 1.83 | $1.6B | $260.2M | $1.3B | $893.4M | — |
| FY2024 · to Dec 31 | $5.4B | 79.5% | $1.4B | $4.2B | 76.7% | 6.97 | $542.3M | $252.4M | $289.9M | $1.2B | — |
| FY2023 · to Dec 31 | $5B | 80.5% | $1.3B | $1.4B | 28.0% | 2.30 | $895.8M | $253M | $642.8M | $879.6M | — |
| FY2022 · to Dec 31 | $4.5B | 83.8% | $1.5B | $1.5B | 34.1% | 2.44 | $1.2B | $244.6M | $973.6M | $1.7B | — |
| FY2021 · to Dec 31 | $5.2B | 76.1% | $1.7B | $1.5B | 28.7% | 2.38 | $1.7B | $325.8M | $1.4B | $512.8M | — |
| FY2020 · to Dec 31 | $4.4B | 75.4% | $897.6M | $823.4M | 18.8% | 1.30 | $1.1B | $407M | $647.3M | $625.4M | — |
Every number comes from Edwards Lifesciences Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.